Please assess the completion status of the following clinical trial:

Trial Title: Rituximab in Pretreated Elderly or Unfit B-CLL Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of CD20 positive chronic B lymphocytic leukemia (BCLL) confirmed by biopsy or flow-cytometry.~* Previously treated patients with stage Rai I-IV and progressive disease (according to IWCLL 2008 guidelines).~Active B-CLL is defined by at least one of the following:~At least one of the disease related symptoms:~* Constitutional symptoms:~* Weight loss \>10% within the previous 6 months;~* Fatigue (e.g., WHO performance status \>/=2);~* Fever \>/=38C \>/=2 weeks without evidence of infection;~* Night sweats for more than 1 month without evidence of infection.~* Evidence of progressive marrow failure as manifested by development of, or worsening of, anemia and/or thrombocytopenia~* Autoimmune hemolysis and/or thrombocytopenia poorly responsive to corticosteroid therapy.~* Massive (i.e., \>/=6 cm bellow left costal margin) or progressive or symptomatic splenomegaly.~* Massive lymphadenopathy or conglomerates (i.e., \>/=10 cm in largest diameter) or progressive or symptomatic lymphadenopathy.~* Progressive lymphocytosis with an increase \>50% over a 2-month period or an anticipated doubling time of less than 6 months. In patients with initial blood lymphocyte counts of less than 30x10\^9/L LDT should not be used as a single parameter to define treatment indication. Marked hypogammaglobulinemia or the development of a monoclonal protein in the absence of any of the above criteria for active disease is not sufficient for protocol therapy.~* Either of the following:~* 18 years of age or older with impaired performance status (CIRS \> 6) and /or~* 65 years of age or older with any performance status.~* Signed informed consent form.~Exclusion Criteria:~* Intolerance to exogenous protein or known severe reaction to the administration of Rituximab.~* Active infection.~* Cancer radiotherapy, biological therapy or chemotherapy within 3 weeks prior to Study Day 1.~* TBC or fungal infection within the past 6 months even if adequately controlled by treatment.~* Severe organ deficiency preventing the participation in the study.~* Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1.~* Active peptic ulcer.~* Inadequately controlled diabetes mellitus.~* Suspected or confirmed B-CLL CNS disease.~* Known to be HIV positive.~* Difficult to control, uncooperative patients.~* Allergic disorders in need of chronic glucocorticoid therapy.~* Other oncological diseases requiring active treatment (except hormonal therapy).~* Pregnancy and breastfeeding.~* Patients of reproductive potential who are not using effective methods of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- R-HDMP (Type: EXPERIMENTAL): Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete